Suppr超能文献

细胞周期蛋白D1和E的表达在预测肺鳞状细胞癌短期生存中的作用

The expression of cyclins D1 and E in predicting short-term survival in squamous cell carcinoma of the lung.

作者信息

Anton R C, Coffey D M, Gondo M M, Stephenson M A, Brown R W, Cagle P T

机构信息

Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA.

出版信息

Mod Pathol. 2000 Nov;13(11):1167-72. doi: 10.1038/modpathol.3880215.

Abstract

Cyclins D1 (cD1) and E (cE) are G1 phase cyclins believed to participate in the pathogenesis of malignancy. Overexpression of cD1 has been reported to influence prognosis in squamous cell carcinomas (SCC) of the larynx, but was not significant in a limited study of non-small cell lung cancers (NSCLC). Altered expression of cE has been proposed as another potential prognostic marker in malignancy but its possible role in NSCLC has not been elucidated. In order to determine the prognostic value of cD1 and cE in NSCLC, paraffin-embedded sections of 467 NSCLC were immunostained with monoclonal antibody to cD1 (1:500, PharMingen, San Diego, CA) and 400 NSCLC with MA to cE (1:2500, PharMingen) using an enhanced sensitivity avidin-biotin complex technique. The number of tumor cells with nuclear and/or cytoplasmic immunopositivity was graded on a scale of: 0 = less than 1%, 1 = 1 to 10%, 2 = 10 to 25%, 3 = 25 to 50%, 4 = 50 to 75%, 5 = more than 75%. Results were correlated with survival by Kaplan-Meier survival plot using Stat-View software (Abacus Concepts, Berkeley, CA). Overall, 426 NSCLC with cD1 and 360 NSCLC with cE had adequate follow-up (median, 76 mo) for survival analysis. Both cyclins independently showed significance in prognosis of SCC but not other cell types. For cD1, absence of immunostaining was associated with worse prognosis than any immunopositivity for all stages of SCC (P = .025). For cE, Stage I and II SCC with less than 50% immunopositivity had a worse prognosis (P = .029). Of 70 Stage I and II SCC immunostained for both monoclonal antibodies, 55% of patients with tumors that demonstrated both absence of cD1 staining and cE immunopositivity in less than 50% of cells were dead at 5 years compared to 35% of patients with tumors that demonstrated positive staining with cD1 and cE immunopositivity in more than 50% of cells. These results strongly suggest cD1 and cE can independently predict prognosis in early stage SCC. Worse prognosis was associated with loss of expression, consistent with mechanisms other than overexpression of these cyclins in the progression of SCC.

摘要

细胞周期蛋白D1(cD1)和E(cE)是G1期细胞周期蛋白,被认为参与恶性肿瘤的发病机制。据报道,cD1的过表达会影响喉鳞状细胞癌(SCC)的预后,但在一项针对非小细胞肺癌(NSCLC)的有限研究中,其影响并不显著。cE表达的改变已被认为是恶性肿瘤的另一个潜在预后标志物,但其在NSCLC中的可能作用尚未阐明。为了确定cD1和cE在NSCLC中的预后价值,对467例NSCLC的石蜡包埋切片用抗cD1单克隆抗体(1:500,PharMingen,圣地亚哥,加利福尼亚州)进行免疫染色,对400例NSCLC用抗cE单克隆抗体(1:2500,PharMingen)采用增强敏感性抗生物素蛋白-生物素复合物技术进行免疫染色。对具有核和/或细胞质免疫阳性的肿瘤细胞数量按以下标准分级:0 = 小于1%,1 = 1%至10%,2 = 10%至25%,3 = 25%至50%,4 = 50%至75%,5 = 大于75%。使用Stat-View软件(Abacus Concepts公司,伯克利,加利福尼亚州)通过Kaplan-Meier生存曲线将结果与生存率进行关联分析。总体而言,426例有cD1数据和360例有cE数据的NSCLC患者有足够的随访时间(中位随访时间为76个月)用于生存分析。两种细胞周期蛋白在SCC的预后中均独立显示出显著性,但在其他细胞类型中则不然。对于cD1,在SCC的所有阶段,无免疫染色与比任何免疫阳性更差的预后相关(P = 0.025)。对于cE,免疫阳性率低于50%的I期和II期SCC预后较差(P = 0.029)。在70例I期和II期SCC中同时用两种单克隆抗体进行免疫染色,55%的肿瘤细胞cD1染色缺失且cE免疫阳性率低于50%的患者在5年后死亡,而肿瘤细胞cD1和cE免疫阳性率高于50%的患者中这一比例为35%。这些结果强烈表明cD1和cE可独立预测早期SCC的预后。预后较差与表达缺失相关,这与这些细胞周期蛋白在SCC进展过程中的过表达以外的机制一致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验